Home

Overcoming anxiety

Peace of Mind is the initiative developed by Neuraxpharm in partnership with Maudsley Learning, aiming to shed light on the impact of anxiety and provide support to those affected by it.

Learn more 
Scroll to explore

International Epilepsy Day

An initiative highlighting the importance of a rapid intervention in prolonged convulsive seizures

Watch Video 
Scroll to explore

Driving change

Neuraxpharm
Commitment

Know more about Neuraxpharm

1 in 4 people in the world will be affected by mental or neurological disorders at some point in their lives. Roughly every family will have at least one afflicted person in the home.

The wellbeing of those suffering from these disorders is at the heart of all we do. They are the center around whom we investigate and create our solutions.

Our drive and commitment have led us into a leadership position in Europe, specializing in high-quality yet affordable pharmaceuticals for the treatment of central nervous system disorders.

We think of the doctors, the pharmacists, the caretakers and the families. We are your expert CNS specialist.

Researching the early detection, prevention and treatment of common CNS disorders

Key research areas

Epilepsy

Sleep

Stress

Alzheimer's

Depression

Pain

Psychological wellbeing in children

Obsessive compulsive disorder

See all disorders

Health and wellness

Visit our section on Health and wellness and start taking care of yourself

Go to Health and Wellness

Neuraxpharm
News

As experts in CNS disorders, we bring you the latest news, product launches and innovative initiatives we constantly undertake to always stay ahead of developments in the CNS area.

CMO Nx

Neuraxpharm appoints Vikas Mohan Sharma as Chief Medical Officer

Vikas brings over 25 years of healthcare and clinical research experience leading high-value clinical & medical scientific teams across multiple therapeutic areas to deliver successful developmental and program milestones in large pharma and Clinical Research Organizations (CRO). 

Neuraxpharm Pharmaceuticals awarded EcoVadis Silver Medal for sustainability

Neuraxpharm Pharmaceuticals has once again received a Silver Medal from EcoVadis, placing us among the top 15% of companies assessed globally for sustainability management performance.

Neuraxpharm and Pharmathen enter into strategic co-development agreement to develop long-acting injectable therapies

New therapies will allow patients greater choice and flexibility in the control of CNS disorders

Neuraxpharm reports another year of sustained growth and international expansion

CNS specialist continues growth strategy across Europe and beyond, optimizing commercial efficiency and maintaining strong focus on innovation
ESG 2023

Neuraxpharm launches its ESG Report for 2023

Neuraxpharm is pleased to announce the publication of its ESG Report for 2023, highlighting the continued efforts made by the Company to improve its sustainability performance.

Neuraxpharm supports World Mental Health Day

This year to support World Mental Health Day we launch our campaign, Peace of Mind – Overcoming Anxiety

Neuraxpharm Blog

Understand more about psychiatric and neurological disorders. Our team of health care professionals and expert journalists across Europe works to consistently bring you scientifically solid, trustable information to answer your concerns.

Chronic pain

What are the differences between Acute and Chronic Pain

Pain is a complex phenomenon to study, understand and treat. It is a personal experience with a multidimensional character influenced by biological, psychological and social factors. There is a misconception that the difference between acute and chronic pain. When considering pain and time, we could say that there are three types of pain: acute pain, persistent pain and chronic pain.

Read more

Alzheimer's

Is Alzheimer’s hereditary?

In 95% of cases, Alzheimer’s disease is the result of a combination of genetic, environmental and lifestyle factors that affect the person over time. The other 5% of cases, defined as early or hereditary Alzheimer’s, usually appear before the age of 65, with more aggressive and/or rapid deterioration, mainly due to mutations in the genes

Alzheimer's

10 first symptoms of Alzheimer’s

Alzheimer’s disease has many faces. Depending on the region that is affected, the symptoms will vary. Just as the manifestation of the first symptoms of Alzheimer’s in a young person (under 65 years of age) is not the same as in a person in their seventies or eighties. Even so, there are common elements that can alert us that something is happening, and we can take measures to delay the appearance of the symptoms of Alzheimer’s disease.
Treating Cognitive Impairment in Multiple Sclerosis

Multiple sclerosis

Cognitive impairment in Multiple Sclerosis: a reality to treat as early as possible

Cognitive impairment has been reported at all phases and all subtypes of multiple sclerosis (MS). The severity and type of cognitive impairment varies among individuals and can be observed both in early and in later stages. We should promote primary prevention of cognitive decline, in part through interventions and healthy lifestyles that promote brain maintenance.